Global Pulmonary Arterial Hypertension (PAH) Market is forecasted to grow at a CAGR of 4.95% during 2016-2021

Date: 16 August 2016

Increasing prevalence of PAH majorly in developed countries combined with strong focus on R&D of investigational drugs is supporting the market for PAH. 

According to Azoth Analytics research report, “Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Trends, Opportunities and Forecasts (2016-2021) - (By Drug Class -Endothelin Receptor Antagonists, Prostacyclin & Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa)”, Global Pulmonary Arterial Hypertension Market is projected to exhibit a CAGR of over ~ 4.95% during 2016 – 2021, driven by the rising prevalence of PAH globally. On the basis of market segment, the market has been segmented into major drug classes, namely, Endothelin receptor antagonists (ERA), Prostacyclin and Prostacyclin Analogs, Phosphodiesterase V Inhibitors (PDE5) and others.

By definition, PAH occurs with increase in mean pulmonary arterial pressure (PAP) to =25 mmHg at rest, and a mean primary capillary wedge pressure of =15 mmHg. As PAH develops, blood flow through the pulmonary arteries is restricted and the right side of the heart becomes enlarged due to the increased strain of pumping blood through the lungs, leading to constriction in pulmonary arteries. PAH being a rare disease, estimated prevalence varies from 15-50 cases per million in US and Europe. PAH still remains under diagnosed mainly in developing and under developed countries. 

From the market point of view, ERA holds the largest share among the drug classes driven by the major revenue generating drug, Tracleer. However, prostacyclin drugs are expected to witness stronger growth in the forecast period, due to its effectiveness as a vasodilator. Also, with major pipeline drugs such as launch of Uptravi is expected to push the prostacyclin segment. 

Among the regions, North America holds the major market due to a robust healthcare infrastructure combined with growing research and development in PAH along with better diagnosis among the patients within the region.

The report titled “Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Trends, Opportunities and Forecasts (2016-2021) - (By Drug Class -Endothelin Receptor Antagonists, Prostacyclin & Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa)’’ has analysed the potential of Global Pulmonary Arterial Hypertension Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global pulmonary arterial hypertension market. Additionally, the report also highlights market entry strategies for various companies across the globe.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others), By Region (North America, Europe, APAC, Latin America, MEA) and By Country (USA, Canada, UK, Germany, Japan, Brazil, South Africa).



...